Home / Business and Economy / IQVIA's AI Edge: Stock Surges on Analyst Upgrade
IQVIA's AI Edge: Stock Surges on Analyst Upgrade
4 Jul
Summary
- IQVIA is a leader in AI-driven clinical trials.
- Analysts expect strong EPS growth for fiscal 2026 and 2027.
- The stock has a 'Strong Buy' rating with an average price target increase.
Durham, North Carolina-based IQVIA Holdings Inc. (IQV) is a key player in the life sciences and healthcare industries, offering clinical research services and healthcare intelligence. The company operates through three primary segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
IQVIA is currently experiencing a surge in its stock value, attributed partly to its strong position in the rapidly growing AI-driven clinical trial market. Analysts have expressed significant optimism, with the stock holding an overall 'Strong Buy' rating. This positive outlook is supported by projections for robust earnings per share growth in the upcoming fiscal years.
Looking ahead, analysts forecast EPS of $2.74 for Q2 2026, an 8.3% increase from the previous year. For the full fiscal year 2026, EPS is projected at $11.60, with further growth to $12.97 expected in fiscal 2027. These upward revisions, coupled with a recent price target upgrade to $249 from Baird, highlight the market's confidence in IQVIA's future performance.
